↓ Skip to main content

Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma

Overview of attention for article published in PLOS ONE, May 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
2 news outlets
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
189 Dimensions

Readers on

mendeley
155 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma
Published in
PLOS ONE, May 2013
DOI 10.1371/journal.pone.0064498
Pubmed ID
Authors

Julia Köritzer, Veronika Boxhammer, Andrea Schäfer, Tetsuji Shimizu, Tobias G. Klämpfl, Yang-Fang Li, Christian Welz, Sabina Schwenk-Zieger, Gregor E. Morfill, Julia L. Zimmermann, Jürgen Schlegel

Abstract

Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite multimodal treatments including surgery, chemotherapy and radiotherapy the prognosis remains poor and relapse occurs regularly. The alkylating agent temozolomide (TMZ) has been shown to improve the overall survival in patients with malignant gliomas, especially in tumors with methylated promoter of the O6-methylguanine-DNA-methyltransferase (MGMT) gene. However, intrinsic and acquired resistance towards TMZ makes it crucial to find new therapeutic strategies aimed at improving the prognosis of patients suffering from malignant gliomas. Cold atmospheric plasma is a new auspicious candidate in cancer treatment. In the present study we demonstrate the anti-cancer properties of different dosages of cold atmospheric plasma (CAP) both in TMZ-sensitive and TMZ-resistant cells by proliferation assay, immunoblotting, cell cycle analysis, and clonogenicity assay. Importantly, CAP treatment restored the responsiveness of resistant glioma cells towards TMZ therapy. Concomitant treatment with CAP and TMZ led to inhibition of cell growth and cell cycle arrest, thus CAP might be a promising candidate for combination therapy especially for patients suffering from GBMs showing an unfavorable MGMT status and TMZ resistance.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 3%
France 1 <1%
Unknown 150 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 40 26%
Student > Master 19 12%
Student > Doctoral Student 18 12%
Student > Bachelor 18 12%
Researcher 16 10%
Other 17 11%
Unknown 27 17%
Readers by discipline Count As %
Medicine and Dentistry 25 16%
Biochemistry, Genetics and Molecular Biology 20 13%
Physics and Astronomy 20 13%
Engineering 20 13%
Agricultural and Biological Sciences 11 7%
Other 28 18%
Unknown 31 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2013.
All research outputs
#1,681,256
of 22,711,242 outputs
Outputs from PLOS ONE
#21,802
of 193,913 outputs
Outputs of similar age
#14,995
of 195,531 outputs
Outputs of similar age from PLOS ONE
#530
of 4,888 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 193,913 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,531 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 4,888 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.